Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 8/20 | 0.76 |
| ▸ | HTR1D | P28221 | 5/20 | 0.76 |
| ▸ | HTR1A | P08908 | 3/20 | 0.71 |
| ▸ | HTR6 | P50406 | 10/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | DRD1 | P21728 | 1/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2182107 | 1.00 | HTR1B (0.76) | HTR1BHTR1DHTR1AHTR6CHRM2 | |
| SCHEMBL697582 | 1.00 | HTR1B (0.76) | HTR1BHTR1DHTR1AHTR6CHRM2 | |
| SCHEMBL29827195 | 1.00 | HTR1B (0.76) | HTR1BHTR1DHTR1AHTR6CHRM2 | |
| Oxalic Acid SCHEMBL2727283 | 0.94 | HTR1B (0.68) | HTR1BHTR1DHTR1AHTR6CHRM2 | |
| Oxalic Acid SCHEMBL2725284 | 0.94 | HTR1B (0.68) | HTR1BHTR1DHTR1AHTR6CHRM2 | |
| Fumaric Acid SCHEMBL2180504 | 0.90 | HTR1B (0.63) | HTR1BHTR1DHTR1AHTR6CHRM2 | |
| Fumaric Acid SCHEMBL2182475 | 0.90 | HTR1B (0.63) | HTR1BHTR1DHTR1AHTR6CHRM2 | |
| SCHEMBL8888890 | 0.87 | HTR1B (0.60) | HTR1BHTR1DHTR1AHTR6 | |
| SCHEMBL8508432 | 0.86 | HTR1B (1.00) | HTR1BHTR1DHTR1AHTR6CHRM2 | |
| SCHEMBL8208343 | 0.86 | HTR1B (1.00) | HTR1BHTR1DHTR1AHTR6CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012025772-A1 | PROCESS FOR PREPARING PURE 5-BROMO-3-[(R)-1-METHYL-PYRROLIDIN-2-YLMETHYL]-1H-INDOLE, INTERMEDIATE FOR ELETRIPTAN | POTLURI RAMESH BABU (IN) | 2012-03-01 | — | — | WO | claimed |
| WO-2009142771-A2 | SALTS OF (R)-5-(2-PHENYLSULPHONYLETHENYL)-3-(N- METHYLPYRROLIDIN-2-YLMETHYL)-1H-INDOLE, 5-BROMO-3-[(R)-1- METHYL-PYRROLIDIN-2- YLMETHYL]-1H-INDOLE AND OF ELETRIPTAN | PLUS CHEMICALS, S.A. (CH) | 2009-11-26 | — | — | WO | claimed |
| EP-2038273-A1 | A PROCESS FOR PREPARING 5-BROMO-3-[(R)-1-METHYL-PYRROLIDIN-2-YLMETHYL]-1H-INDOLE | Plus Chemicals B.V. (NL) | 2009-03-25 | — | — | EP | claimed |
| WO-2008150500-A1 | A PROCESS FOR PREPARING 5-BROMO-3-[(R)-1-METHYL-PYRROLIDIN-2-YLMETHYL]-1H-INDOLE | PLUS CHEMICALS, S.A. (CH) | 2008-12-11 | — | — | WO | claimed |
| CN-100430388-C | Improved process for the preparation of alpha-polymorphic eletriptan hydrobromide | PFIZER (US) | 2008-11-05 | — | — | CN | claimed |
| EP-1660485-B1 | IMPROVED PROCESS FOR PREPARING ALPHA-POLYMORPHIC ELETRIPTAN HYDROBROMIDE | PFIZER LTD (GB) | 2006-12-27 | — | — | EP | claimed |
| CN-1823060-A | Improved process for preparing alpha-polymorphic eletriptan hydrobromide | PFIZER (US) | 2006-08-23 | — | — | CN | claimed |
| US-20050245591-A1 | Process | PFIZER INC. | 2005-11-03 | — | — | US | claimed |
| EP-1373254-B1 | Process for the preparation of the anti-migraine drug eletriptan | PFIZER LTD (GB) | 2005-11-02 | — | — | EP | claimed |
| CN-1199969-C | New process for the preparation of the anti-migraine drug | PFIZER LTD (US) | 2005-05-04 | — | — | CN | claimed |
| US-20050059828-A1 | Process for the preparation of eletriptan | PFIZER INC. | 2005-03-17 | — | — | US | claimed |
| US-20050020663-A1 | Process | FURLONG PATRICK JOSEPH (IE) | 2005-01-27 | — | — | US | claimed |
| CN-1487932-A | New process for the preparation of the anti-migraine drug | — | 2004-04-07 | — | — | CN | claimed |
| US-20030166704-A1 | New process | PFIZER INC. | 2003-09-04 | — | — | US | claimed |
| CN-1039322-C | Indole derivatives | PFIZER (US) | 1998-07-29 | — | — | CN | claimed |
| EP-0592438-B1 | INDOLE DERIVATIVES | PFIZER (US) | 1997-08-27 | — | — | EP | claimed |
| EP-0592438-A1 | INDOLE DERIVATIVES. | PFIZER (US) | 1994-04-20 | — | — | EP | claimed |
| WO-1992006973-A1 | INDOLE DERIVATIVES | PFIZER INC. (US) | 1992-04-30 | — | — | WO | claimed |
| US-12303564-B2 | Composite chitosan-tannin-active agent compositions and methods of making and using same | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-05-20 | — | — | US | disclosed |
| WO-1992006973-A1 | INDOLE DERIVATIVES | PFIZER INC. (US) | 1992-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245591-A1 | Process | TPSD1, TPSAB1, TPSB2 | HTR1B 81/4885HTR1D 78/4885HTR1A 29/4885 |
| US-20050059828-A1 | Process for the preparation of eletriptan | TFPI, HTR3A, HTR3E | HTR1B 33/4885HTR1D 21/4885HTR1A 15/4885 |
| US-20050020663-A1 | Process | TPSD1, TPSAB1, TPSB2 | HTR1B 81/4885HTR1D 78/4885HTR1A 29/4885 |
| US-12303564-B2 | Composite chitosan-tannin-active agent compositions and methods of making and using same | TTPA, CHIA, CHIT1 | HTR1B 3603/4885HTR1D 3856/4885HTR1A 2312/4885 |
| US-20030166704-A1 | New process | TFPI, HTR4, HTR5A | HTR1B 32/4885HTR1D 24/4885HTR1A 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.